SAT497 Radiofrequency Ablation of Thyroid Cancer in A Patient With Steinert’s Disease

• Published in: Journal of the Endocrine Society 2023-10, Vol.7 (Supplement_1)
• Main Authors: Solis Pazmiño, Andrea Paola, Carvajal, Mishel Arboleda, Godoy, Richard, Garcia, Cristhian
• Format: Article
• Language: English
• Subjects: Thyroid
• ISSN: 2472-1972; 2472-1972
• DOI: 10.1210/jendso/bvad114.1970

Disclosure: A.P. Solis Pazmiño: None. M. Arboleda Carvajal: None. R. Godoy: None. C. Garcia: None. Background: Radiofrequency Ablation (RFA) is a non-surgical, minimally invasive technique for benign or microcarcinoma thyroid nodule (TN); and it has emerged as an alternative option for patients deemed at high risk for surgery. Steinert’s Disease or Myotonic dystrophy type 1 (DM1) is a genetic multisystem disease that affects almost all organs and tissues, including the thyroid. In these patients the prevalence of TN is increased, regardless they are benign or malignant. Patients with DM1 commonly have post-anesthetic complications such as cardiorespiratory arrest. Clinical Case: A young man diagnosed with DM1 and no other comorbidities came to the office for a TN. The patient was asymptomatic and had normal thyroid function. Nothing relevant was found on physical examination, and no cervical lymph nodules were found. The thyroid ultrasonography (US) showed a 12x11x13 mm solid isoechoic left lobe nodule, with microcalcifications, irregular borders and the color-flow Doppler US detected increased perfusion, classifying it as a TI-RADS 5 nodule, elastography score of 2.2, and Bethesda VI. Due to DM1 high risk of surgery, the patient underwent RFA with no complications and successful recovery. Results: At the first month follow-up after RFA, the thyroid nodule was fibrosed with a size of 10x14x15 mm and with a volume of 1,11 cc. The thyroid function was normal without late complications. Conclusions: RFA is a non-invasive and effective technique for the treatment of benign and malignant TN. It is safe and very useful in cases where surgery is contraindicated or in patients with a high probability of post-surgical or post-anesthetic complications. Data on a longer follow-up are needed to confirm long-term efficacy. Presentation Date: Saturday, June 17, 2023